The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
In vivo genome editing using Staphylococcus aureus Cas9
Open accessAbstract
The RNA-guided endonuclease Cas9 has emerged as a versatile genome-editing platform. However, the size of the commonly used Cas9 from Streptococcus pyogenes (SpCas9) limits its utility for basic research and therapeutic applications that use the highly versatile adeno-associated virus (AAV) delivery vehicle. Here, we characterize six smaller Cas9 orthologues and show that Cas9 from Staphylococcus aureus (SaCas9) can edit the genome with efficiencies similar to those of SpCas9, while being more than 1 kilobase shorter. We packaged SaCas9 and its single guide RNA expression cassette into a single AAV vector and targeted the cholesterol regulatory gene Pcsk9 in the mouse liver. Within one week of injection, we observed >40% gene modification, accompanied by significant reductions in serum Pcsk9 and total cholesterol levels. We further assess the genome-wide targeting specificity of SaCas9 and SpCas9 using BLESS, and demonstrate that SaCas9-mediated in vivo genome editing has the potential to be efficient and specific.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Also, the requirement of a specific PAM Sequence for targeted genome editing is crucial, and even though it reduces off-target activity, it often results in suboptimal DNA cleavage, editing efficiencies (Ran et al., 2015; Edraki et al., 2019) and restricting the scope of targeted edition.”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Ran et al., 2015
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Cas9 genomic localization is delimited by the protospacer adjacent motif (PAM), which is NGG for SpCas9 while evolved variants of SpCas9 tolerate a broader range of PAM sequences17–21.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The SpCas9 homolog derived from Staphylococcus aureus (SaCas9) has been extensively characterized as a highly efficient and significantly smaller alternative to SpCas9.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“It recognizes an NNGRRT PAM (where R = A or G)20.”
From One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids (2023) · cites this paper as [20]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Recent advancements in gene-editing technologies have led to the development of artificial Cas9 variants with relaxed PAM specificities, which improve efficiency but are associated with an increase in off-target effects and a decrease in target specificity (Ran et al., 2015).”
From Emerging applications of gene editing technologies for the development of climate-resilient crops (2025) · cites this paper as Ran et al., 2015
Experimental — accuracy not yet measured
In the citing paper
“Recently, a smaller form of Cas9 was developed, and shown capable of packing and delivery with sgRNA by AAV in vivo12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“Adenovirus or adeno-associated virus (AAV)-mediated CRISPR-Cas9 delivery has been successfully applied to knockout genes in the mouse brain and liver12,13.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“A smaller form of Cas9 (Staphylococcus aureus Cas9), which fits into AAV vectors, has been recently used to knockout genes by NHEJ in the mouse liver. More than 40% indel formations in Pcsk9 locus was reported12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“For example, less than 10% indels at the Apob locus in the mouse liver was reported in the same study12.”
From Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo (2016) · cites this paper as [12]
In the citing paper
“However, the large genetic size of Cas9 (~ 4.5 kb) and the total plasmid size (> 7 kb) significantly increase the difficulty of delivery and expression of CRISPR/Cas9 systems [94].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [94]
In the citing paper
“Although the newly discovered Cas9 form from Staphylococcus aureus strain (SaCas9) is about 1 kb shorter than SpCas9, the overall genetic size is still too large for application [94, 140].”
From Non-viral delivery systems for CRISPR/Cas9-based genome editing: challenges and opportunities (2018) · cites this paper as [94]
In the citing paper
“The Cas9 from Staphylococcus aureus (SaCas9) is over 1 kb shorter (3.15 kb) than SpCas9 [69].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [69]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationMfold web server for nucleic acid folding and hybridization prediction
Zuker, M. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg595 · Cited by 13,404
WebLogo: A Sequence Logo Generator: Figure 1Preprint
Crooks, G. E., Hon, G. C., Chandonia, J., & Brenner, S. E. (2004) · Genome Research · doi:10.1101/gr.849004 · Cited by 12,480
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes
Barrangou, R., Fremaux, C., Deveau, H., Richards, M., Boyaval, P., Moineau, S., Romero, D. A., & Horvath, P. (2007) · Science · doi:10.1126/science.1138140 · Cited by 5,947
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationHigh-Frequency off-Target Mutagenesis Induced by CRISPR-Cas Nucleases in Human Cells
Fu, Y., Foden, J. A., Khayter, C., Maeder, M. L., Reyon, D., Joung, J. K., & Sander, J. D. (2013) · Nature Biotechnology · doi:10.1038/nbt.2623 · Cited by 3,292
Cited by
Sorted by citations
Items 501–600 of 1,009
Kostyushev, D. S., Brezgin, S., Kostyusheva, A., Zarifyan, D., Goptar, I. A., & Chulanov, V. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03021-8 · Cited by 90
Si, X., Zhang, H., Wang, Y., Chen, K., & Gao, C. (2020) · Nature Protocols · doi:10.1038/s41596-019-0238-3 · Cited by 93
CRISPR/Cas genome editing improves abiotic and biotic stress tolerance of crops
Li, Y., Wu, X., Zhang, Y., & Zhang, Q. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.987817 · Cited by 98
Self-citationCRISPR/Cas9 Landscape: Current State and Future Perspectives
Tyumentsev, A. I., Tyumentsev, A. I., & Акимкин, В. Г. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216077 · Cited by 98
Optimization of genome editing through CRISPR-Cas9 engineering
Zhang, J.-H., Adikaram, P. R., Pandey, M., Genis, A., & Simonds, W. F. (2016) · Bioengineered · doi:10.1080/21655979.2016.1189039 · Cited by 94
Genome editing in cardiovascular diseases
Strong, A., & Musunuru, K. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.139 · Cited by 91
Cas9, Cpf1 and C2c1/2/3―What's next?
Nakade, S., Yamamoto, T., & Sakuma, T. (2017) · Bioengineered · doi:10.1080/21655979.2017.1282018 · Cited by 92
Farhang, N., Brunger, J. M., Stover, J. D., Thakore, P. I., Lawrence, B. D., Guilak, F., Gersbach, C. A., Setton, L. A., & Bowles, R. D. (2017) · Tissue Engineering Part A · doi:10.1089/ten.tea.2016.0441 · Cited by 90
Biomaterials as vectors for the delivery of CRISPR–Cas9
Eoh, J. H., & Gu, L. (2019) · Biomaterials Science · doi:10.1039/c8bm01310a · Cited by 92
CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives
Chan, Y.-T., Lu, Y., Wu, J., Zhang, C., Tan, H., Bian, Z., Wang, N., & Feng, Y. (2022) · Theranostics · doi:10.7150/thno.71144 · Cited by 93
Turan, S., Farruggio, A. P., Srifa, W., Day, J., & Calos, M. P. (2016) · Molecular Therapy · doi:10.1038/mt.2016.40 · Cited by 88
Dronina, J., Samukaitė-Bubnienė, U., & Ramanavičius, A. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112867 · Cited by 88
Base Editing in Plants: Applications, Challenges, and Future Prospects
Azameti, M. K., & Dauda, W. P. (2021) · Frontiers in Plant Science · doi:10.3389/fpls.2021.664997 · Cited by 88
Hepatocyte-derived exosomes from early onset obese mice promote insulin sensitivity through miR-3075
Ji, Y., Luo, Z., Gao, H., Reis, F. C. G., Bandyopadhyay, G. K., Jin, Z., Manda, K. A., Isaac, R., Yang, M., Fu, W., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00444-1 · Cited by 91
Vascular aging: Molecular mechanisms and potential treatments for vascular rejuvenation
Mistriotis, P., & Andreadis, S. T. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.05.006 · Cited by 89
Advanced domestication: harnessing the precision of gene editing in crop breeding
Lyzenga, W. J., Pozniak, C. J., & Kagale, S. (2021) · Plant Biotechnology Journal · doi:10.1111/pbi.13576 · Cited by 85
Beyond Native Cas9: Manipulating Genomic Information and Function
Mitsunobu, H., Teramoto, J., Nishida, K., & Kondo, A. (2017) · Trends in biotechnology · doi:10.1016/j.tibtech.2017.06.004 · Cited by 87
CRISPR-Cas based antiviral strategies against HIV-1
Wang, G., Zhao, N., Berkhout, B., & Das, A. T. (2017) · Virus Research · doi:10.1016/j.virusres.2017.07.020 · Cited by 86
Duchêne, B. L., Cherif, K., Iyombe-Engembe, J.-P., Guyon, A., Rousseau, J., Ouellet, D. L., Barbeau, X., Lagüe, P., & Tremblay, J. P. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.08.010 · Cited by 89
Wang, Y., Liu, K. I., Sutrisnoh, N.-A. B., Srinivasan, H., Zhang, J., Li, J., Zhang, F., Richard, J. L. C., Xing, H., Shanmugam, R., et al. (2018) · Genome biology · doi:10.1186/s13059-018-1445-x · Cited by 91
Self-citationTargeting hepatitis B virus cccDNA using CRISPR/Cas9
Kennedy, E. M., Kornepati, A. V. R., & Cullen, B. R. (2015) · Antiviral Research · doi:10.1016/j.antiviral.2015.10.004 · Cited by 86
Puchta, H. (2015) · The Plant Journal · doi:10.1111/tpj.13100 · Cited by 87
Effective screen of CRISPR/Cas9-induced mutants in rice by single-strand conformation polymorphism
Zheng, X., Yang, S., Zhang, D., Zhong, Z., Tang, X. D., Deng, K., Zhou, J., Qi, Y., & Zhang, Y. (2016) · Plant Cell Reports · doi:10.1007/s00299-016-1967-1 · Cited by 86
Chemically Modified Cpf1-CRISPR RNAs Mediate Efficient Genome Editing in Mammalian Cells
McMahon, M. A., Prakash, T. P., Cleveland, D. W., Bennett, C. F., & Rahdar, M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.031 · Cited by 87
Zabaleta, N., Barberia, M., Martín-Higueras, C., Zapata‐Linares, N., Betancor, I., Rodríguez-Diaz, S., Martínez-Turrillas, R., Torella, L., Vales, Á., Olagüe, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07827-1 · Cited by 86
Development and Application of Base Editors
Yang, B., Yang, L. C., & Chen, J. (2019) · The CRISPR Journal · doi:10.1089/crispr.2019.0001 · Cited by 87
Guide RNA engineering for versatile Cas9 functionality
Nowak, C. M., Lawson, S., Zerez, M., & Bleris, L. G. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw908 · Cited by 83
Hallmarks of cancer: The CRISPR generation
Moses, C., García‐Bloj, B., Harvey, A. R., & Blancafort, P. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.01.002 · Cited by 90
Improving CRISPR-Cas9 Genome Editing Efficiency by Fusion with Chromatin-Modulating Peptides
Ding, X. L., Seebeck, T., Feng, Y., Jiang, Y., Davis, G. D., & Chen, F. (2019) · The CRISPR Journal · doi:10.1089/crispr.2018.0036 · Cited by 87
Base and Prime Editing Technologies for Blood Disorders
Antoniou, P., Miccio, A., & Brusson, M. (2021) · Frontiers in Genome Editing · doi:10.3389/fgeed.2021.618406 · Cited by 94
Zhang, X., Jin, H., Huang, X., Chaurasiya, B., Dong, D., Shanley, T. P., & Zhao, Y. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110196 · Cited by 90
Genome editing in crop improvement: Present scenario and future prospects
Miglani, G. S. (2017) · Journal of Crop Improvement · doi:10.1080/15427528.2017.1333192 · Cited by 86
MicroRNA-focused CRISPR-Cas9 library screen reveals fitness-associated miRNAs
Kurata, J. S., & Lin, R.-J. (2018) · RNA · doi:10.1261/rna.066282.118 · Cited by 82
Tseng, S. ‐., Kempson, I. M., Huang, K., Li, H., Fa, Y., Ho, Y., Liao, Z., & Yang, P. (2018) · ACS Nano · doi:10.1021/acsnano.8b02813 · Cited by 86
McCutcheon, S. R., Swartz, A. M., Brown, M. C., Barrera, A., Amador, C. M., Siklenka, K., Humayun, L. L., ter Weele, M. A., Isaacs, J. M., Reddy, T. E., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01554-0 · Cited by 89
Rapid Evolution of Manifold CRISPR Systems for Plant Genome Editing
Lowder, L. G., Malzahn, A. A., & Qi, Y. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.01683 · Cited by 88
Towards personalised allele-specific CRISPR gene editing to treat autosomal dominant disorders
Christie, K. A., Courtney, D., DeDionisio, L., Chao-Shern, C., Majumdar, S. D., Mairs, L., Nesbit, M. A., & Moore, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-16279-4 · Cited by 83
Chen, P., Zhou, J., Wan, Y., Liu, H., Li, Y., Liu, Z., Wang, H., Lei, J., Zhao, K., Zhang, Y., et al. (2020) · Genome biology · doi:10.1186/s13059-020-01989-2 · Cited by 86
Genome editing in sea urchin embryos by using a CRISPR/Cas9 system
Lin, C.-Y., & Su, Y. (2015) · Developmental Biology · doi:10.1016/j.ydbio.2015.11.018 · Cited by 82
Toro, C. A., Wright, H., Aylwin, C. F., Ojeda, S. R., & Lomniczi, A. (2017) · Nature Communications · doi:10.1038/s41467-017-02512-1 · Cited by 81
Progress and Challenges for Live-Cell Imaging of Genomic Loci using CRISPR-Based Platforms
Wu, X., Mao, S., Ying, Y., Krueger, C. J., & Chen, A. K. (2019) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2018.10.001 · Cited by 84
Self-citationLi, Q., Zhao, Q., Zhang, J., Zhou, L., Zhang, W., Chua, B. T., Chen, Y., Xu, L. M., & Li, P. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.066 · Cited by 81
Liu, Q., He, D., & Xie, L. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007480 · Cited by 86
Harnessing nanoparticles for the efficient delivery of the CRISPR/Cas9 system
Rahimi, H., Salehiabar, M., Charmi, J., Barsbay, M., Ghaffarlou, M., Razlighi, M. R., Davaran, S., Khalilov, R. I., Sugiyama, M., Nosrati, H., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100895 · Cited by 83
dCas9-based gene editing for cleavage-free genomic knock-in of long sequences
Wang, C., Qu, Y., Cheng, J. K. W., Hughes, N. W., Zhang, Q., Wang, M., & Cong, L. (2022) · Nature Cell Biology · doi:10.1038/s41556-021-00836-1 · Cited by 82
Self-citationGene Editing With CRISPR/Cas9 RNA-Directed Nuclease
Doetschman, T., & Georgieva, T. G. (2017) · Circulation Research · doi:10.1161/circresaha.116.309727 · Cited by 91
Jarrett, K. E., Lee, C. M., Giorgi, M. D., Hurley, A. E., Gillard, B. K., Doerfler, A. M., Li, A., Pownall, H. J., Bao, G., & Lagor, W. R. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311221 · Cited by 84
Therapeutic potential of CRISPR/Cas9 gene editing in engineered T‐cell therapy
Gao, Q., Dong, X., Xu, Q., Zhu, L., Wang, F., Hou, Y., & Chao, C. (2019) · Cancer Medicine · doi:10.1002/cam4.2257 · Cited by 85
Genome editing methods in animal models
Lee, H., Yoon, D. E., & Kim, K. (2020) · Animal Cells and Systems · doi:10.1080/19768354.2020.1726462 · Cited by 83
Expanding the plant genome editing toolbox with recently developed CRISPR–Cas systems
Wada, N., Osakabe, K., & Osakabe, Y. (2022) · PLANT PHYSIOLOGY · doi:10.1093/plphys/kiac027 · Cited by 83
CRISPR–Cas9 Gene Editing: Curing Genetic Diseases by Inherited Epigenetic Modifications
Kolanu, N. D. (2024) · Global Medical Genetics · doi:10.1055/s-0044-1785234 · Cited by 93
Bichet, D. G., & Böckenhauer, D. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.02.010 · Cited by 81
New traits in crops produced by genome editing techniques based on deletions
van de Wiel, C. C. M., Schaart, J. G., Lotz, L. A. P., & Smulders, M. J. M. (2017) · Plant Biotechnology Reports · doi:10.1007/s11816-017-0425-z · Cited by 80
Imaging Specific Genomic DNA in Living Cells
Chen, B., Guan, J., & Huang, B. (2016) · Annual Review of Biophysics · doi:10.1146/annurev-biophys-062215-010830 · Cited by 77
Kim, H., Choi, J., & Won, K. (2020) · BMC Plant Biology · doi:10.1186/s12870-020-02665-0 · Cited by 82
In Vivo Ovarian Cancer Gene Therapy Using CRISPR-Cas9
He, Z., Zhang, Y., Yang, Y., Ma, C., Wang, P., Du, W. T., Li, L., Xiang, R., Song, X., Zhao, X., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.209 · Cited by 81
Kumar, N., Stanford, W., de Solis, C., Aradhana, Abraham, N. D., Dao, T.-M. J., Thaseen, S., Sairavi, A., Gonzalez, C. U., & Ploski, J. E. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00413 · Cited by 79
Ji, H., Jiang, Z., Lu, P., Ma, L., Li, C., Pan, H., Fu, Z., Qu, X., Wang, P., Deng, J., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.7 · Cited by 80
Application of the CRISPR/Cas system for genome editing in microalgae
Zhang, Y., Jiang, J., Shi, T., Sun, X., Zhao, Q., Huang, H., & Ren, L. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-09726-x · Cited by 82
Duan, W., Guo, M., Yi, L., Liu, Y., Li, Z., Ma, Y., Zhang, G., Liu, Y., Bu, H., Song, X., et al. (2019) · Gene Therapy · doi:10.1038/s41434-019-0116-1 · Cited by 79
Mouse γ-Synuclein Promoter-Mediated Gene Expression and Editing in Mammalian Retinal Ganglion Cells
Qizhao, W., Zhuang, P., Huang, H., Li, L., Liu, L., Webber, H. C., Dalal, R., Siew, L., Fligor, C. M., Chang, K., et al. (2020) · Journal of Neuroscience · doi:10.1523/jneurosci.0102-20.2020 · Cited by 82
A simple, flexible and high‐throughput cloning system for plant genome editing via CRISPR‐Cas system
Kim, H., Kim, S., Ryu, J., Choi, M. K., Kweon, J., Kang, B., Ahn, H., Bae, S., Kim, J., Kim, J., et al. (2016) · Journal of Integrative Plant Biology · doi:10.1111/jipb.12474 · Cited by 78
Antiviral Goes Viral: Harnessing CRISPR/Cas9 to Combat Viruses in Humans
Soppe, J. A., & Lebbink, R. J. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.04.005 · Cited by 79
Lainšček, D., Kadunc, L., Keber, M. M., Hafner‐Bratkovič, I., Romih, R., & Jerala, R. (2018) · ACS Synthetic Biology · doi:10.1021/acssynbio.8b00192 · Cited by 78
Staphylococcus aureus Cas9 is a multiple-turnover enzyme
Yourik, P., Fuchs, R. T., Mabuchi, M. Y., Curcuru, J. L., & Robb, G. B. (2018) · RNA · doi:10.1261/rna.067355.118 · Cited by 75
A Survey of Genome Editing Activity for 16 Cas12a Orthologs
Zetsche, B., Abudayyeh, O. O., Gootenberg, J. S., Scott, D. A., & Zhang, F. (2019) · The Keio Journal of Medicine · doi:10.2302/kjm.2019-0009-oa · Cited by 78
Self-citationCRISPR Therapeutics for Duchenne Muscular Dystrophy
Erkut, E. J. N., & Yokota, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031832 · Cited by 82
Current approaches in CRISPR-Cas9 mediated gene editing for biomedical and therapeutic applications
Bhattacharjee, G., Gohil, N., Khambhati, K., Mani, I., Maurya, R., Karapurkar, J. K., Gohil, J., Chu, D., Vu‐Thi, H., Alzahrani, K. J., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.02.005 · Cited by 84
Iyombe-Engembe, J.-P., Ouellet, D. L., Barbeau, X., Rousseau, J., Chapdelaine, P., Lagüe, P., & Tremblay, J. P. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.58 · Cited by 80
Shen, C., Hsu, M., Chang, C.-W., Lin, M., Hwu, J. R., Tu, Y., & Hu, Y. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1165 · Cited by 82
Next stop for the CRISPR revolution: RNA‐guided epigenetic regulators
Vora, S., Tuttle, M. L., Cheng, J. Y., & Church, G. M. (2016) · FEBS Journal · doi:10.1111/febs.13768 · Cited by 75
Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma
Kong, H., Ju, E., Yi, K., Xu, W., Lao, Y., Cheng, D., Zhang, Q., Tao, Y., Li, M., & Ding, J. (2021) · Advanced Science · doi:10.1002/advs.202102051 · Cited by 77
CRISPR/Cas-Based Modifications for Therapeutic Applications: A Review
Bharathkumar, N., Abraham, S., Meera, P., Aksah, S., Muthu, K., Saravanan, K. M., & Anand, T. (2021) · Molecular Biotechnology · doi:10.1007/s12033-021-00422-8 · Cited by 80
Sahel, D. K., Vora, L. K., Saraswat, A. L., Sharma, S., Monpara, J. D., D’souza, A. A., Mishra, D., Tryphena, K. P., Kawakita, S., Khan, S. U., et al. (2023) · Advanced Science · doi:10.1002/advs.202207512 · Cited by 79
Song, Z., Tao, Y., Liu, Y., & Li, J. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1444437 · Cited by 81
Small molecules as inhibitors of PCSK9: Current status and future challenges
Xu, S., Luo, S., Zhu, Z., & Xu, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.011 · Cited by 85
Applications of CRISPR Genome Engineering in Cell Biology
Wang, F., & Qi, L. S. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.08.004 · Cited by 79
Hupfeld, M., Trasanidou, D., Ramazzini, L., Klumpp, J., Loessner, M. J., & Kilcher, S. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky544 · Cited by 77
Cas9 Allosteric Inhibition by the Anti-CRISPR Protein AcrIIA6
Fuchsbauer, O., Swuec, P., Zimberger, C., Amigues, B., Levesque, S., Agudelo, D., Duringer, A., Chaves-Sanjuán, A., Spinelli, S., Rousseau, G. M., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.012 · Cited by 76
Synthetic multi-layer nanoparticles for CRISPR-Cas9 genome editing
Tang, H., Zhao, X., & Jiang, X. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.03.001 · Cited by 80
Nanomedicine-based cancer immunotherapy: recent trends and future perspectives
Lakshmanan, V., Jindal, S., Packirisamy, G., Ojha, S. K., Lian, S., Kaushik, A. K., Alzarooni, A. I. M. A., Metwally, Y. H. H., Thyagarajan, S. P., Jung, Y. D., et al. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00299-4 · Cited by 78
Deep learning models to predict the editing efficiencies and outcomes of diverse base editors
Kim, N., Choi, S.-C., Kim, S., Song, M., Seo, J. H., Min, S., Park, J., Cho, S., & Kim, S. (2023) · Nature Biotechnology · doi:10.1038/s41587-023-01792-x · Cited by 78
Precise genome-editing in human diseases: mechanisms, strategies and applications
Zheng, Y., Li, Y., Zhou, K., Li, T., VanDusen, N. J., & Hua, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01750-2 · Cited by 91
Huang, J., Chen, M., Whitley, M. J., Kuo, H.-C., Xu, E. S., Walens, A., Mowery, Y. M., Mater, D. V., Eward, W. C., Cardona, D. M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15999 · Cited by 75
CRISPR–Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics
Ghosh, D., Venkataramani, P., Nandi, S., & Bhattacharjee, S. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0726-0 · Cited by 83
Versatile and robust genome editing with Streptococcus thermophilus CRISPR1-Cas9Preprint
Agudelo, D., Carter, S., Velimirovic, M., Duringer, A., Rivest, J.-F., Levesque, S., Loehr, J., Mouchiroud, M., Cyr, D., Waters, P. J., et al. (2020) · Genome Research · doi:10.1101/gr.255414.119 · Cited by 75
Development and Application of CRISPR/Cas in Microbial Biotechnology
Ding, W., Zhang, Y., & Shi, S. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00711 · Cited by 81
Bombesin-Like Peptide Recruits Disinhibitory Cortical Circuits and Enhances Fear Memories
Melzer, S., Newmark, E., Mizuno, G. O., Hyun, M., Philson, A. C., Quiroli, E., Righetti, B., Gregory, M. R., Huang, K. W., Levasseur, J., et al. (2020) · Cell · doi:10.1016/j.cell.2021.09.013 · Cited by 79
Genome Editing and Its Applications in Model Organisms
Ma, D., & Liu, F. (2015) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2015.12.001 · Cited by 81
Basila, M., Kelley, M. L., & Smith, A. V. B. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188593 · Cited by 73
In Vivo Genome Editing as a Therapeutic Approach
Ho, B. X., Loh, S. J. H., Chan, W., & Soh, B.-S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092721 · Cited by 81
Novel CRISPR/Cas applications in plants: from prime editing to chromosome engineering
Huang, T., & Puchta, H. (2021) · Transgenic Research · doi:10.1007/s11248-021-00238-x · Cited by 77
Morphogene‐assisted transformation of Sorghum bicolor allows more efficient genome editing
Aregawi, K., Shen, J., Pierroz, G., Bucheli, C., Sharma, M. K., Dahlberg, J. A., Owiti, J., & Lemaux, P. G. (2021) · Plant Biotechnology Journal · doi:10.1111/pbi.13754 · Cited by 74
Cas11 enables genome engineering in human cells with compact CRISPR-Cas3 systems
Tan, R., Krueger, R., Gramelspacher, M. J., Zhou, X., Xiao, Y., Ke, A., Hou, Z., & Zhang, Y. (2022) · Molecular Cell · doi:10.1016/j.molcel.2021.12.032 · Cited by 76
CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration
Burnight, E. R., Giacalone, J. C., Cooke, J. A., Thompson, J. R., Bohrer, L. R., Chirco, K. R., Drack, A. V., Fingert, J. H., Worthington, K. S., Wiley, L. A., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.03.003 · Cited by 79
Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update
Lin, F.-L., Wang, P.-Y., Chuang, Y.-F., Wang, J.-H., Wong, V. H. Y., Bui, B. V., & Liu, G.-S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.029 · Cited by 74
Pickar‐Oliver, A., Gough, V., Bohning, J. D., Liu, S., Robinson-Hamm, J. N., Daniels, H., Majoros, W. H., Devlin, G. W., Asokan, A., & Gersbach, C. A. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.09.003 · Cited by 78
Transcriptomic mapping uncovers Purkinje neuron plasticity driving learning
Chen, X., Du, Y., Broussard, G. J., Kislin, M., Yuede, C. M., Zhang, S., Dietmann, S., Gabel, H. W., Zhao, G., Wang, S. S. ‐., et al. (2022) · Nature · doi:10.1038/s41586-022-04711-3 · Cited by 70
Inner Ear Drug Delivery for Sensorineural Hearing Loss: Current Challenges and Opportunities
Liu, S. S., & Yang, R. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.867453 · Cited by 79
Advances in Nanoparticles as Non-Viral Vectors for Efficient Delivery of CRISPR/Cas9
Kim, M., Hwang, Y., Lim, S., Jang, H., & Kim, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091197 · Cited by 77
Metadata
- Authors
- Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., Koonin, E. V., Sharp, P. A., & Zhang, F.
- Affiliations
- Broad Institute (US)
- Massachusetts Institute of Technology (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- National Institutes of Health (US)
- Corresponding author
- Zhang, Feng
- ORCID
- Venue
- Nature
- Published
- 2015-04
- Volume
- 520
- Issue
- 7546
- Pages
- 186-191
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4393360
- OpenAlex
- W2070614858
- Cited by
- 2,687
- References
- 51
- Citations by year
- 2026: 126 · 2025: 167 · 2024: 180 · 2023: 199 · 2022: 285 · 2021: 263 · 2020: 274 · 2019: 261 · 2018: 264 · 2017: 288 · 2016: 264 · 2015: 113
- FWCI
- 134.53
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- PMC
- Funders
- Howard Hughes Medical Institute
- National Institute of Mental Health (DP1MH100706)
- National Eye Institute (R01EY024259, P30EY012196)
- National Cancer Institute (R01CA133404, P01CA042063, P30CA014051, P30-CA-14051, P01 CA 42063)
- National Institute of General Medical Sciences (R01GM034277, T32GM008313, R01 GM34277, T32GM007753)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK097768)
- National Center for Chronic Disease Prevention and Health Promotion (5DP1-MH100706)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- SaCas9, SpCas9, CRISPR/Cas9, in vivo gene editing, adeno-associated virus delivery, PCSK9, cholesterol regulation, targeting specificity, single guide RNA
- MeSH terms
- Proprotein Convertase 9, Animals, Base Sequence, Cholesterol, Genetic Engineering, Liver, Male, Mice, Inbred C57BL, Serine Endopeptidases, Staphylococcus aureus, Substrate Specificity, Genome, Gene Targeting, Proprotein Convertases, Mice, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
